Product Name: Pegcetacoplan
Form: Free base
CAS No: 2019171-69-6
Molar Mass: 43520.1
Chemical Formula: C1970H3848N50O947S
Synonyms: APL-2
Storage: Store at -20℃
Target: complement inhibitor
Application:
Pegcetacoplan (CAS: 2019171-69-6) is a pegylated small molecule inhibitor of complement component 3 (C3) used in the treatment of various complement-mediated disorders. It functions by selectively binding to C3 and inhibiting its cleavage into biologically active fragments, thereby blocking the activation of the complement cascade. Pegcetacoplan is particularly effective in conditions characterized by dysregulated complement activation, such as paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. In pharmaceutical chemistry, pegcetacoplan's targeted inhibition of C3 represents a significant advancement in the management of complement-related disorders, offering a specific and effective therapeutic approach to modulate the dysregulated immune response underlying these conditions. Its application underscores its importance in improving outcomes and quality of life for patients with PNH and other complement-mediated diseases. Additionally, ongoing research explores pegcetacoplan's potential in other complement-driven disorders and its role in combination therapies, highlighting its versatility in immune-mediated therapeutics.
Current Research:
Pegcetacoplan is a pegylated, synthetic complement C3 inhibitor designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder. PNH is characterized by the destruction of red blood cells due to abnormal activation of the complement system, leading to hemolysis, anemia, and thrombosis. Pegcetacoplan works by inhibiting complement C3, a central component of the complement system, which is involved in immune-mediated destruction of red blood cells. By blocking the activation of C3, Pegcetacoplan reduces hemolysis, improves anemia, and helps prevent the thrombotic complications associated with PNH.
Mechanism of Action
Pegcetacoplan exerts its effects by specifically binding to and inhibiting the complement protein C3, a crucial part of the innate immune system that plays a key role in the cascade of events leading to complement activation. By blocking C3 activation, Pegcetacoplan prevents the formation of C3a and C3b fragments, which are involved in the formation of the membrane attack complex (MAC). The MAC is responsible for the lysis of red blood cells in PNH patients. By inhibiting this process, Pegcetacoplan reduces the excessive activation of the complement system, decreasing hemolysis and improving symptoms associated with PNH. Pegcetacoplan’s pegylation enhances its half-life, allowing for less frequent dosing compared to other complement inhibitors.
Indications and Uses
Pegcetacoplan is primarily indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. PNH is characterized by the destruction of red blood cells, leading to anemia, fatigue, and increased risk of thrombosis. Pegcetacoplan helps manage these symptoms by inhibiting the complement system and reducing hemolysis. In clinical settings, Pegcetacoplan is administered as a subcutaneous injection, typically once a week, although the dosing schedule may vary depending on the patient’s response and the severity of their condition. Pegcetacoplan is often used in patients who are not adequately controlled by other treatments, such as eculizumab, or in patients who experience breakthrough hemolysis despite complement inhibition.
Efficacy and Clinical Benefits
Clinical trials have shown that Pegcetacoplan significantly reduces hemolysis and improves anemia in patients with PNH. In a pivotal trial, Pegcetacoplan demonstrated superiority over eculizumab, a traditional complement inhibitor, in reducing lactate dehydrogenase (LDH) levels, a biomarker of hemolysis. Pegcetacoplan also resulted in greater improvements in hemoglobin levels and reduced the need for blood transfusions, which are common in PNH patients due to anemia. The drug has been shown to provide a more complete and sustained inhibition of complement activation, leading to better clinical outcomes, such as reduced fatigue and improved quality of life. Additionally, Pegcetacoplan has demonstrated a favorable safety profile compared to other treatments, with fewer complications such as infections, which are often associated with more complete complement inhibition.
Safety and Tolerability
Pegcetacoplan is generally well tolerated, but like other complement inhibitors, it may increase the risk of infections, particularly those caused by encapsulated bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. Vaccination against these pathogens is recommended before initiating therapy. Other common side effects include injection site reactions, such as pain, redness, or swelling at the site of administration. Some patients may experience headaches, diarrhea, or fatigue. Serious adverse events are rare, but patients should be monitored regularly for signs of infections or other complications. It is also important to monitor for potential liver dysfunction, as the drug is metabolized in the liver.
Advantages and Limitations
The main advantage of Pegcetacoplan is its ability to provide more complete and sustained inhibition of the complement system compared to other therapies such as eculizumab. This translates into greater reductions in hemolysis and improved hemoglobin levels, which can reduce the need for blood transfusions and improve patient quality of life. Pegcetacoplan’s subcutaneous administration offers a more convenient alternative to intravenous therapies, which may require more frequent hospital visits. However, its use is still associated with the risk of serious infections, which limits its use in certain populations. Additionally, its high cost and the need for vaccination before treatment initiation may pose logistical challenges in some healthcare settings.
Future Directions
Research into Pegcetacoplan is ongoing, with studies focusing on expanding its use to other complement-mediated diseases, such as atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). Future trials may explore its potential in combination with other therapies or its long-term impact on reducing thrombotic events and improving survival in patients with PNH. Further research will also assess its safety and efficacy in broader patient populations, including those with different genetic backgrounds or those who have experienced inadequate responses to other complement inhibitors. In addition, continued efforts to reduce the cost of treatment and improve access to Pegcetacoplan may help address some of the limitations currently associated with its use.
Reference:
Hoy, S. M. (2021). Pegcetacoplan: first approval. Drugs, 81, 1423-1430.
Get a Quote
LinkPeptide
